🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Defining a Target Population to Effectively Test a Neuroprotective Drug ahajournals.org/doi/10.1161/ST… The paper explains rational behind inclusion criteria of the APRIL trial. AppToll: Neuroprotection in acute ischemic stroke. How to maximize chances to show clinical benefit

ANGIOCAT randomized trial results @ #ISC21: Direct to Angio + flat panel CT in suspected LVO pts (including IVT eligible) leads to almost 30 min reduction in door to reperfusion and better outcomes compared to conventional CT/CTA evaluation. @ManuRequenaRuiz Marc

JNIS Latest Content Fernandez-Sanchez, Marc, Adnan H. Siddiqui, MD, Ofir Arad et al use an in vitro #stroke #thrombectomy model to evaluate the suction force of a novel aspiration catheter bit.ly/3cHXRFJ

Direct to Angio Suite (DTAS) workflow on stroke patient: Admission NIHSS= 16 3 hours since stroke onset LVO suspected Door to reperfusion (Aspiration): 18 minutes NIHSS 24h= 1 Every 30 minutes delay before treatment reduces the chance of a good outcome by 14%

Should we trust CTP in the hyperacute period? Tudor G. Jovin, MD Sunil Sheth, MD ? We all know the answer ..

Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion | NEJM nejm.org/doi/full/10.10… Inability to show a significant difference in outcomes does not mean there is no difference. Had the study not been redesigned mid trial, results would likely have favored thrombectomy.

Se han publicado oficialmente los resultado del #BASIC trial Ya hemos hablado harto desde su análisis durante el #ESOWSO2020 No cambiará la práctica x el momento Lo mejor? El nuevo formato de resumen del NEJM Ps: 👏 Brazilian team nejm.org/doi/full/10.10…

Arkep Haris Kamal Wondwossen Gebreamanuel Tekle Osman Mir Kaushik Parsha S. R Ammar Abdulrazzak, MD #stroke #NoLVOleftbehind #TimeisBrain

Dr. Jovin is right, we determined the detrimental effect of additional passes, recanalization with any passes is still better than NO recanalization. When to Stop Detrimental Effect of Device Passes. doi.org/10.1161/STROKE…

Paving the way towards DIRECT TRANSFER TO ANGIOSUITE in Stroke: First patient WE-TRUST stroke study - News | Philips philips.com/a-w/about/news…

A mentor’s love for their trainees can be measured in tracked changes

Direct to Angiography Suite Without Stopping for Computed Tomography Imaging in Acute Stroke ja.ma/3Cap0fp via JAMA Neurology part of JAMA Network Why not DTAS your next case?

We are thrilled to have you among us ⁦Isa⁩ your skills will be a great addition to our team! 👏🏻 Vall d'Hebron Institut de Recerca⁩ ⁦Alejandro Tomasello W⁩ ⁦Marc⁩ ⁦@ManuRequenaRuiz⁩ Vall d'Hebron #neurointerventional #research #talent #future #innovation linkedin.com/posts/marta-de…

Clinical Results of the Advanced Neurovascular Access Catheter System Combined With a Stent Retriever in Acute Ischemic Stroke (SOLONDA) ahajournals.org/doi/10.1161/ST…

Latest in basic science - bit.ly/3MqIcd7 - Li J et al showed up to 79% variability in devices’ tracking performance. Hybrid coil and braid reinforcement configuration and DACs’ distal wall thickness are significant contributory factors to ease navigation. Marc

Patient-reported outcome measures after thrombectomy in patients with acute stroke: fine-tuning the modified Rankin Scale jnis.bmj.com/content/early/…

In this RCT, in nonurban areas in Catalonia, Spain, there was no significant difference in 90-day neurological outcomes btwn transportation to a local stroke center vs a thrombectomy-capable referral center in pts w suspected large-vessel occlusion stroke. ja.ma/3LJRkcJ

Molt bona defensa de tesi de la, ara ja si, Dra Marta Olivé de la Unitat d’Ictus del nostre servei de #neurologia Vall d'Hebron Neurociències Vall d'Hebron Vall d'Hebron Institut de Recerca Publicada en Stroke i J Neurointer Surgery. Enhorabona a Marta Carlos Molina Marc i a la resta de l’equip!!!

Enhorabuena a los ganadores del Premio de la SEN Ictus-2022 Científico: Natalia Perez de la Ossa y Marc Ribó!

Tomorrow at 9.00 am France time SLICE - Worldwide / Next Frontiers / Workshops, co-PI's Montpellier Team Cases Caroline Arquizan lapergue Bertrand, MD, PhD Tudor G. Jovin, MD will present primary results of LASTE (randomized trial of MT in large core pts. ASPECTS 0-5). Median core = 150 ml with 56% ASPECTS 0-2.Please join us: masterandfellow.com/slice/ww